Working groups
Patrick completed his Bachelor of Science in 2022 with majors in chemistry and biochemistry. Before joining the Burnet Diagnostics Initiative (BDI), he undertook research at the Bio21 Institute to understand the mutation-driven behaviour of a unique sulfatase protein in M. tuberculosis.
We’re developing a novel class of antibody and delivery technologies to provide enhanced protection and therapeutic performance for coronaviruses and other respiratory infections.
A rapid point-of-care (POC) test for liver disease biomarkers could improve the management of acute and chronic liver disease and reduce the progression to liver cancer in Australia and globally.